Valeant Pharmaceuticals Intl Inc (NYSE:VRX)‘s stock had its “buy” rating restated by stock analysts at Rodman & Renshaw in a research note issued to investors on Tuesday, MarketBeat.Comreports.
VRX has been the topic of several other reports. BMO Capital Markets reissued a “market perform” rating and set a $133.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, March 15th. Piper Jaffray lowered Valeant Pharmaceuticals Intl from a “neutral” rating to an “underweight” rating in a research report on Tuesday, March 15th. Jefferies Group reissued a “buy” rating and set a $53.00 price target (down from $106.00) on shares of Valeant Pharmaceuticals Intl in a research report on Monday, March 14th. Morgan Stanley reduced their price target on Valeant Pharmaceuticals Intl from $98.00 to $39.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 16th. Finally, CIBC began coverage on Valeant Pharmaceuticals Intl in a research report on Monday, November 30th. They set a “sector perform” rating and a $90.00 price target on the stock. Six investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $93.44.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 10.04% during trading on Tuesday, hitting $31.89. 53,315,498 shares of the stock were exchanged. The stock has a market cap of $10.94 billion and a PE ratio of 18.32. Valeant Pharmaceuticals Intl has a one year low of $25.99 and a one year high of $263.81. The stock’s 50 day moving average price is $73.05 and its 200 day moving average price is $113.19.